FLSM
APTX

Frazier Life Sciences Management’s Aptinyx Inc. Common Stock APTX Stock Holding History

Frazier Life Sciences Management’s Portfolio APTX Stock Details APTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,883,244
Closed -$537K – 51
2022
Q4 		$537K Hold
1,883,244
– – 0.03% 42
2022
Q3 		$693K Hold
1,883,244
– – 0.05% 42
2022
Q2 		$1.05M Hold
1,883,244
– – 0.1% 40
2022
Q1 		$4.28M Buy
+1,883,244
New +$5.64M 0.36% 37

Other funds holding APTX

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Frazier Life Sciences Management's APTX Position: Q1 2023 in Review

Frazier Life Sciences Management sold out of Aptinyx Inc. Common Stock (APTX) in Q1 2023, closing a stake of 1,883,244 shares — an estimated $537K sold.

Frazier Life Sciences Management first reported a position in APTX in Q1 2022 and held it in 4 quarters. The position peaked at $4.28M in Q1 2022. 32 funds tracked by Wall St. Rank hold APTX as of Q1 2023.

  • Frazier Life Sciences Management reported no remaining Aptinyx Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Frazier Life Sciences Management sold 1,883,244 Aptinyx Inc. Common Stock shares in Q1 2023, an estimated $537K.
  • Frazier Life Sciences Management first reported a position in Aptinyx Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Frazier Life Sciences Management's Aptinyx Inc. Common Stock position peaked at $4.28M in Q1 2022.
  • 32 funds tracked by Wall St. Rank held Aptinyx Inc. Common Stock as of Q1 2023.

Based on Frazier Life Sciences Management's 13F filing for Q1 2023, filed 15 May 2023.